Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

2.60
+0.290012.55%
Post-market: 2.52-0.0797-3.07%18:47 EDT
Volume:279.66K
Turnover:705.94K
Market Cap:4.77M
PE:-0.10
High:2.89
Open:2.31
Low:2.28
Close:2.31
52wk High:39.96
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.78
T/O Rate:16.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.64
PE(LYR):-0.04

Loading ...

HCW Biologics - Treatment of Third Dose Cohort (8 Mcg/Kg) Underway in Phase 1 Trial

THOMSON REUTERS
·
Jun 16

HCW Biologics - HCW9302 Well Tolerated With No Dose-Limiting Toxicities Reported

THOMSON REUTERS
·
Jun 16

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

GlobeNewswire
·
Jun 16

HCW Biologics Shareholders Approve Governance and Capital Measures

TIPRANKS
·
Jun 16

HCW Biologics shareholders approve reverse stock split proposal at annual meeting

Reuters
·
Jun 16

HCW Biologics Registers Resale of Up to 5.7 Million Shares

MT Newswires Live
·
Jun 08

BRIEF-HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock

Reuters
·
Jun 08

HCW Biologics registers to sell 5.69M shares of common stock for holders

TIPRANKS
·
Jun 08

HCW Biologics - Proposed Resale of up to 5.69 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 08

HCW Biologics Wins Nasdaq Extension to Avoid Delisting

TIPRANKS
·
Jun 01

HCW Biologics gets Nasdaq extension to regain $1 minimum bid compliance by July 29

Reuters
·
Jun 01

HCW Biologics Is Maintained at Buy by Maxim Group

Dow Jones
·
May 29

HCW Biologics CEO buys $160K in common stock

TIPRANKS
·
May 28

HCW Biologics CEO Hing C. Wong acquires 113,879 common shares worth $160,499

Reuters
·
May 28

HCW Biologics director Scott T. Garrett reports purchase of 177,936 shares for $249,501.12

Reuters
·
May 28

HCW Biologics CFO Rebecca Byam acquires 14,235 shares for $19,998.68

Reuters
·
May 28

HCW Biologics Reclaims Key Cell Therapy License Rights

TIPRANKS
·
May 27

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents From Wugen

THOMSON REUTERS
·
May 27

HCW Biologics Inc - Buys Rights for No Cost and Retains 2.2 Mln Wugen Shares

THOMSON REUTERS
·
May 27

HCW Biologics regains full ex vivo rights to HCW9206, HCW9201 from Wugen

Reuters
·
May 27